Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis

Blauvelt, AndrewAndrewBlauveltTSEN-FANG TSAILangley, Richard GRichard GLangleyMiller, MeganMeganMillerShen, Yaung-KaungYaung-KaungShenYou, YinYinYouYang, Ya-WenYa-WenYangPapp, Kim AKim APappPuig, LuisLuisPuig2022-09-202022-09-2020220190-9622https://scholars.lib.ntu.edu.tw/handle/123456789/621248Guselkumab effectively treats moderate-to-severe psoriasis.enadverse events; biologics; guselkumab; infections; malignancy; psoriasis; safety[SDGs]SDG3Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasisjournal article10.1016/j.jaad.2021.11.004347982012-s2.0-85114514084WOS:000840267700017https://api.elsevier.com/content/abstract/scopus_id/85114514084